|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's range||28.43 - 28.43|
|52-week range||25.81 - 32.10|
|Beta (5Y monthly)||1.32|
|PE ratio (TTM)||20.52|
|Forward dividend & yield||0.44 (1.55%)|
|Ex-dividend date||10 May 2021|
|1y target est||N/A|
Cara Therapeutics (NASDAQ: CARA) was a hot stock on Tuesday. One of the formerly clinical-stage biotech's drug candidates won FDA approval, and investors reacted in the usual manner. The biotech company's most promising drug, Korsuva --- developed with Switzerland-based Vifor Pharma -- addresses this medical challenge sufficiently to win that all-important FDA approval.
CARA gets a significant boost with FDA approval for Korsuva injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis.
This is Cole Herlitz-Ferguson with Stern Investor Relations and welcome to Cara Therapeutics' second quarter 2021 financial results and update conference call. Before we begin, let me remind you that statements made on today's call regarding matters that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.